Top Ten most popular articles on Pharmafile.com this week
pharmafile | October 5, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | EU, Jannsen, NHS, Novartis, Novo Nordisk, dementia, top 10
As September came to a close and October began the UK was hit hard in the headlines after American firm Recardio halted clinical trials in Scotland and England while the government were accused of using Brexit to avoid EU led antibiotic resistance legislation.
However innovations in immunotherapy gave hope to those with HIV after an antibody was found to be able to supress the virus for months at a time while NHS England decided to fund Janssen’s HIV treatment Symtuza.
Meanwhile it was revealed that a man died after a leukaemia cell had been mixed in with cells being manufactured into CAR T therapies, while Novo Nordisk cut 650 jobs worldwide in a major R&D overhaul. Check out this week’s top 10 stories at Pharmafile.com!
10. NHS England to fund availability of Janssen’s single tablet HIV combo Symtuza
Great news for HIV patients in the UK as Janssen reveals that NHS England will provide critical funding for its once-daily single tablet regimen of Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), meaning affected individuals will be able to access the drug through regular clinician prescriptions across England.
9. Roche acquires immuno-oncology biotech Tusk in €655m deal
Swiss multinational Roche has acquired the privately held immuno-oncology company Tusk Therapeutics in a deal that could be worth up to €655 million.
8. UK government accused of using Brexit to avoid antimicrobial resistance ruling
The British government has been accused of using Brexit to avoid implementing new EU legislation preventing powerful antibiotics from be used in farming.
7. European countries unprepared for Alzheimer’s innovations, study shows
European healthcare systems are not prepared for new developments in preventative therapies for Alzheimer’s disease, according to research conducted by the American non-profit think tank, the RAND Corporation.
6. Novo Nordisk cuts 650 roles around the world in R&D restructure
Novo Nordisk has announced a wave of jobs cuts as part of a global restructure of its $1 billion R&D business to drive diversification of its pipeline in chronic diseases, affecting hundreds of positions across its operations around the world.
5. Antibody therapy supresses HIV for months after treatment, study shows
Researchers from the New York City based Rockefeller University have developed a novel immunotherapy, which is capable of suppressing HIV for months at a time.
4. Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer
The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged.
3. Are biosimilars key to solving NHS access concerns?
In light of continued austerity gripping the NHS, it was uplifting to hear in July that the health service had generated millions in savings by switching to off-brand medications. Biosimilars formed a key part of this strategy, as Matt Fellows discovers.
2. 20 year old man died after leukaemia cell was accidently mixed into CAR T therapy
A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that were being manufactured into a CAR-T cell therapy, according to researchers at the University of Pennsylvania.
1. Clinical trial halted because of Brexit, UK Government downplays concerns
A clinical trial looking into the safety and efficacy of the drug dutogliptin has been halted due to uncertainties surrounding Brexit.
Related Content
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
